<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Based on the established electrophoretic mobility of <z:chebi fb="0" ids="15765">L-DOPA</z:chebi> and on pathogenetic assumptions, the authors carried out multiple modality treatment employing transcerebral <z:chebi fb="0" ids="15765">L-DOPA</z:chebi> electrophoresis in 48 patients with postencephalic and atherosclerotic <z:hpo ids='HP_0001300'>parkinsonism</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The majority of patients (43 subjects) showed an improvement of various degrees, particularly when <z:hpo ids='HP_0002063'>rigidity</z:hpo> and oligo- and <z:hpo ids='HP_0002067'>bradykinesia</z:hpo> were predominant in the clinical picture of the disease </plain></SENT>
<SENT sid="2" pm="."><plain>Of the 48 patients treated, 29 received <z:chebi fb="0" ids="15765">L-DOPA</z:chebi> per os and 19 patients were given low drug doses </plain></SENT>
<SENT sid="3" pm="."><plain>The therapeutic effect persisted from 2 weeks to 2-3 months </plain></SENT>
</text></document>